Literature DB >> 22892662

Proteinase-activated receptor 2 (PAR(2)) in cholangiocarcinoma (CCA) cells: effects on signaling and cellular level.

Roland Kaufmann1, Alexander Hascher, Franziska Mussbach, Petra Henklein, Kathrin Katenkamp, Martin Westermann, Utz Settmacher.   

Abstract

In this study, we demonstrate functional expression of the proteinase-activated receptor 2 (PAR(2)), a member of a G-protein receptor subfamily in primary cholangiocarcinoma (PCCA) cell cultures. Treatment of PCCA cells with the serine proteinase trypsin and the PAR(2)-selective activating peptide, furoyl-LIGRLO-NH(2), increased migration across a collagen membrane barrier. This effect was inhibited by a PAR(2)-selective pepducin antagonist peptide (P2pal-18S) and it was also blocked with the Met receptor tyrosine kinase (Met) inhibitors SU 11274 and PHA 665752, the MAPKinase inhibitors PD 98059 and SL 327, and the Stat3 inhibitor Stattic. The involvement of Met, p42/p44 MAPKinases and Stat3 in PAR(2)-mediated PCCA cell signaling was further supported by the findings that trypsin and the PAR(2)-selective agonist peptide, 2-furoyl-LIGRLO-NH(2), stimulated activating phosphorylation of these signaling molecules in cholangiocarcinoma cells. With our results, we provide a novel signal transduction module in cholangiocarcinoma cell migration involving PAR(2)-driven activation of Met, p42/p44 MAPKinases and Stat3.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22892662     DOI: 10.1007/s00418-012-1006-4

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  49 in total

1.  Molecular cloning of a potential proteinase activated receptor.

Authors:  S Nystedt; K Emilsson; C Wahlestedt; J Sundelin
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

2.  Proteinase-activated receptor-2 (PAR-2): regulation of salivary and pancreatic exocrine secretion in vivo in rats and mice.

Authors:  A Kawabata; H Nishikawa; R Kuroda; K Kawai; M D Hollenberg
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

3.  Chemical and physiological characterization of fluo-4 Ca(2+)-indicator dyes.

Authors:  K R Gee; K A Brown; W N Chen; J Bishop-Stewart; D Gray; I Johnson
Journal:  Cell Calcium       Date:  2000-02       Impact factor: 6.817

4.  Protease activated receptor signaling is required for African trypanosome traversal of human brain microvascular endothelial cells.

Authors:  Dennis J Grab; Jose C Garcia-Garcia; Olga V Nikolskaia; Yuri V Kim; Amanda Brown; Carlos A Pardo; Yongqing Zhang; Kevin G Becker; Brenda A Wilson; Ana Paula C de A Lima; Julio Scharfstein; J Stephen Dumler
Journal:  PLoS Negl Trop Dis       Date:  2009-07-21

5.  A role for protease-activated receptor-2 in pancreatic cancer cell proliferation.

Authors:  Rie Shimamoto; Tetsuji Sawada; Yasutake Uchima; Masafumi Inoue; Kenjiro Kimura; Yoshito Yamashita; Nobuya Yamada; Tamahiro Nishihara; Masaichi Ohira; Kosei Hirakawa
Journal:  Int J Oncol       Date:  2004-06       Impact factor: 5.650

6.  Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis.

Authors:  Xiaoli Shi; Beena Gangadharan; Lawrence F Brass; Wolfram Ruf; Barbara M Mueller
Journal:  Mol Cancer Res       Date:  2004-07       Impact factor: 5.852

Review 7.  c-Met targeted therapy of cholangiocarcinoma.

Authors:  Matei-P Socoteanu; Frank Mott; Gianfranco Alpini; Arthur-E Frankel
Journal:  World J Gastroenterol       Date:  2008-05-21       Impact factor: 5.742

8.  Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.

Authors:  Boris R A Blechacz; Rory L Smoot; Steven F Bronk; Nathan W Werneburg; Alphonse E Sirica; Gregory J Gores
Journal:  Hepatology       Date:  2009-12       Impact factor: 17.425

9.  Met receptor tyrosine kinase transactivation is involved in proteinase-activated receptor-2-mediated hepatocellular carcinoma cell invasion.

Authors:  Roland Kaufmann; Claudia Oettel; Antje Horn; Karl-Jürgen Halbhuber; Annett Eitner; Reimar Krieg; Kathrin Katenkamp; Peter Henklein; Martin Westermann; Frank D Böhmer; Rithwik Ramachandran; Mahmoud Saifeddine; Morley D Hollenberg; Utz Settmacher
Journal:  Carcinogenesis       Date:  2009-06-22       Impact factor: 4.944

10.  Constitutive expression of functionally active protease-activated receptors 1 and 2 in human conjunctival epithelial cells.

Authors:  Timothy J Nickel; Mohammad H Kabir; Jaya Talreja; Daniel J Stechschulte; Kottarappat N Dileepan
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

View more
  5 in total

Review 1.  The Histochemistry and Cell Biology compendium: a review of 2012.

Authors:  Douglas J Taatjes; Jürgen Roth
Journal:  Histochem Cell Biol       Date:  2013-05-12       Impact factor: 4.304

Review 2.  Proteinase-activated receptors (PARs) - focus on receptor-receptor-interactions and their physiological and pathophysiological impact.

Authors:  Frank Gieseler; Hendrik Ungefroren; Utz Settmacher; Morley D Hollenberg; Roland Kaufmann
Journal:  Cell Commun Signal       Date:  2013-11-11       Impact factor: 5.712

3.  Proteinase-activated receptor 2 (PAR2) in hepatic stellate cells - evidence for a role in hepatocellular carcinoma growth in vivo.

Authors:  Franziska Mußbach; Hendrik Ungefroren; Bernd Günther; Kathrin Katenkamp; Petra Henklein; Martin Westermann; Utz Settmacher; Lennart Lenk; Susanne Sebens; Jörg P Müller; Frank-Dietmar Böhmer; Roland Kaufmann
Journal:  Mol Cancer       Date:  2016-07-29       Impact factor: 27.401

Review 4.  Diversification of PAR signaling through receptor crosstalk.

Authors:  Irene Lee-Rivera; Edith López; Ana María López-Colomé
Journal:  Cell Mol Biol Lett       Date:  2022-09-10       Impact factor: 8.702

Review 5.  Protease-activated receptors (PARs)--biology and role in cancer invasion and metastasis.

Authors:  Marek Z Wojtukiewicz; Dominika Hempel; Ewa Sierko; Stephanie C Tucker; Kenneth V Honn
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.